Zsuzsanna Szalai

Heim Pál Gyermekkórház — Hungary

Medicine · Health Sciences

32h-index7.5kcitations126works4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(21), Dermatology and Skin Diseases(21), Cancer Immunotherapy and Biomarkers(19), Allergic Rhinitis and Sensitization(18), Asthma and respiratory diseases(15)

Publications119 total

2‐Hydroxyethyl Methacrylate, Methyl Methacrylate and Ethyl Acrylate Sensitisation: A 7‐Year Retrospective Study
Contact Dermatitis·2025Open Access
International multicenter case series of gestational dupilumab exposure in the treatment of atopic dermatitis: Maternal complications and fetal outcomes
Journal of the American Academy of Dermatology·2025· 1 cited
Neurofibromatosis type 1 (NF1): A Hungarian study – Clinical features and a suggested protocol
Developments in Health Sciences·2025Open Access
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
Journal of Clinical Oncology·2025· 12 citedOpen Access
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC
Journal of Thoracic Oncology·2025· 5 cited
KEYMAKER-U01 substudy 01A: Phase 1/2 study of pembrolizumab plus ifinatamab deruxtecan (I-DXd) or patritumab deruxtecan (HER3-DXd) with or without chemotherapy in untreated stage IV non–small-cell lung cancer.
Journal of Clinical Oncology·2025
Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.
Journal of Clinical Oncology·2025· 4 cited
European Guideline (<scp>EuroGuiDerm</scp>) on atopic eczema: Living update
Journal of the European Academy of Dermatology and Venereology·2025· 23 citedOpen Access
Generalised oedematosus, haemorrhagic rashes: severe disease or benign condition?
Bőrgyógyászati és Venerológiai Szemle·2025Open Access
Differential diagnosis of multiple Café-au-lait macules in the context of clinical presentation and genetic background
Bőrgyógyászati és Venerológiai Szemle·2025Open Access
Increased Phenotype Severity Associated with Splice-Site Variants in a Hungarian Pediatric Neurofibromatosis 1 Cohort: A Retrospective Study
Biomedicines·2025· 3 citedOpen Access
[Molecular pathology of lung adenocarcinomas, EGFR T790M resistance mutation study].
PubMed·2024
LBA49 Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): Expanded analyses from AEGEAN
Annals of Oncology·2024· 21 citedOpen Access
Surgical outcomes with neoadjuvant Durvalumab+chemotherapy followed by adjuvant Durvalumab in resectable NSCLC (AEGEAN)
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie·2024
Association of RNA-sequencing signatures with clinical outcomes of pembrolizumab + chemotherapy in patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) enrolled in the phase 2 KEYNOTE-782 trial.
Journal of Clinical Oncology·2024
Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA)
Italian Journal of Dermatology and Venereology·2024· 9 citedOpen Access
Abstract LB107: Association of circulating free DNA (cfDNA) maximum variant allele frequency (mVAF) levels with clinical outcomes in patients (pts) with metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with pembrolizumab (pembro) + chemotherapy (chemo) in the phase 2 KEYNOTE-782 trial
Cancer Research·2024
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non–small cell lung cancer: KEYNOTE-782
Lung Cancer·2024· 3 citedOpen Access
HUNCHEST-II contributes to a shift to earlier-stage lung cancer detection: final results of a nationwide screening program
European Radiology·2023· 10 citedOpen Access
OA12.05 Surgical Outcomes with Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC (AEGEAN)
Journal of Thoracic Oncology·2023· 8 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

S. Barbarot(15), Mette Deleuran(15), T. Constantin(15), Andreas Wollenberg(14), Uwe Gieler(13), Thomas Werfel(13), Johannes Ring(13), A. Ponyi(13), Antonio Torrelo(12), Dagmar Simon(12), I. Orbán(12), Katalin Molnár(12), Thomas Bieber(11), Beáta Dérfalvi(10), Alain Taı̈eb(9), Carsten Flohr(9), F. Dicső(9), Silvia Novello(8), T. Kálovics(8), Stéphanie Christen‐Zaech(7)